De-nol tab. p / o captivity. 120mg # 32

Dosage form

Creamy white round biconvex film-coated tablets with the inscription gbr 152" extruded on one side and a graphic pattern in the form of a square with discontinuous sides and rounded corners extruded on the other, odorless or with a slight smell of ammonia.

Structure

One film-coated tablet contains:

Active ingredient: bismuth tripotassium dicitrate 304.6 mg (in terms of bismuth oxide Bi2O3 - 120 mg).

Excipients:

corn starch - 70.6 mg, povidone K30 - 17.7 mg, potassium polyacrylate - 23.6 mg, macrogol 6000 - 6.0 mg, magnesium stearate - 2.0 mg.

Sheath:

Opadray OY-S-7366, consists of: hypromellose 5 mPa-s - 3.2 mg, macrogol 6000 - 1.1 mg.

pharmachologic effect

Antiulcer agent with bactericidal activity against Helicobacter pylori.

It also has anti-inflammatory and astringent properties.

In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, chelated compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosions.

By increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the mucous membrane of the gastrointestinal tract to the effects of pepsin, hydrochloric acid, enzymes and bile salts.

Leads to the accumulation of epidermal growth factor in the defect area.

Reduces the activity of pepsin.

Pharmacokinetics

Bismuth subcitrate is practically not absorbed from the gastrointestinal tract.

It is excreted mainly in the feces.

A small amount of bismuth entering the plasma is excreted from the body by the kidneys.

Side effects

From the digestive system: nausea, vomiting, more frequent bowel movements, constipation may occur.

These phenomena are not dangerous to health and are temporary in nature.

Allergic reactions: skin rash, itching of the skin.

With prolonged use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system.

Selling features

Available without a prescription

Special conditions

The drug should not be used for more than 8 weeks.

It is also not recommended to exceed the established daily doses for adults and children during treatment.

During the period of treatment with De-Nol®, other preparations containing bismuth should not be used.

At the end of the course of treatment with the drug in recommended doses, the concentration of the active active substance in the blood plasma does not exceed 3-58 μg / l, and intoxication is observed only at concentrations above 100 μg / l.

When using De-Nola®, stool may turn dark due to the formation of bismuth sulfide.

Slight darkening of the tongue is sometimes noted.

The effect of the drug on the ability to drive vehicles and other mechanisms:

There are no data on the effect of De-Nol® on the ability to drive vehicles and mechanisms.

Indications

Peptic ulcer and duodenal ulcer in the acute phase, including those associated with Helicobacter pylori.

Chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori.

Irritable bowel syndrome, mainly with diarrhea symptoms.

Functional dyspepsia not associated with organic diseases of the gastrointestinal tract.

Contraindications

Decompensated renal failure, pregnancy, lactation, individual drug intolerance, children under 4 years of age.

Pregnancy and lactation:

The use of the drug De-Nol® during pregnancy and lactation is contraindicated.

Drug interactions

Within half an hour before and after taking De-Nola®, it is not recommended to use other medicines internally, as well as to take food and liquids, in particular, antacids, milk, fruits and fruit juices.

This is due to the fact that they at the same time

Name ENG

De-Nol

Clinical and pharmacological group

A drug that has a protective effect on the mucous membrane of the stomach and duodenum.

Antiulcer drug

ATX code

Bismuth subcitrate

Dosage

120 mg

Structure

One film-coated tablet contains: Active ingredient: bismuth tripotassium dicitrate 304.6 mg (in terms of bismuth oxide Bi2O3 - 120 mg).

Excipients: corn starch - 70.6 mg, povidone K30 - 17.7 mg, potassium polyacrylate - 23.6 mg, macrogol 6000 - 6.0 mg, magnesium stearate - 2.0 mg.

Sheath: Opadray OY-S-7366, consists of: hypromellose 5 mPa-s - 3.2 mg, macrogol 6000 - 1.1 mg.

Indications

Peptic ulcer and duodenal ulcer in the acute phase, including those associated with Helicobacter pylori.

Chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori.

Irritable bowel syndrome, mainly with symptoms of diarrhea.

Functional dyspepsia not associated with organic diseases of the gastrointestinal tract.

Storage conditions and periods

The drug should be stored at temperatures between 15 ° and 25 ° C.

Shelf life 4 years.

INN / Active ingredient

bismuth tripotassium dicitrate

Contraindications

Decompensated renal failure, pregnancy, lactation, individual drug intolerance, children under 4 years of age.

,

Specifications

Category

Preparations for the gastrointestinal tract

Scope of the drug

Gastrointestinal tract

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

32

Scope of application

Gastroenterology

Minimum age from

4 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

ASTELLAS

The amount of the dosage form in the primary package

8 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antiseptic intestinal and astringent

Anatomical and therapeutic characteristics

A02BX05 Bismuth tripotassium dicitrate

Dosage form

Film-coated tablets

Expiration date in days

48

The target audience

Children

Package weight, g

twenty

Mode of application

:

The tablets are taken 30 minutes before meals with a little water.

The duration of the course of treatment is 4-8 weeks.

For the next 8 weeks, do not use preparations containing bismuth.

Dosage (volume) of the substance in the preparation

:

bismuth tripotassium dicitrate 304.6 mg, which corresponds to the content of bismuth oxide 120 mg

Information on technical characteristics, delivery set, country of manufacture "